Summary
Sun Pharma has agreed to supply its products to U.S. Medicaid programs at Most Favored Nation (MFN) pricing. The U.S. market is crucial for Sun Pharma, representing its largest market for innovative medicines and contributing approximately 27% of its global revenue.